*Cryptococcus* and dimorphic fungi represent a diverse group of fungal pathogens that share several characteristics including their ability to infect otherwise healthy hosts but can also cause severe infections in immunocompromised individuals. Furthermore, residence within a specific environmental location/niche allows exposure and development of disease \[[@CIW305C1]\]. Infection is typically acquired via inhalation of fungal spores or conidia, and the spectrum of disease can range from asymptomatic acquisition to life-threatening disseminated infection \[[@CIW305C2], [@CIW305C3]\]. Current guidelines for the treatment of cryptococcosis and dimorphic mycoses emphasize the primary role of amphotericin B (AMB) formulations for induction therapy of those with severe disease, while in contrast those with moderate disease typically receive a triazole as initial therapy \[[@CIW305C4]--[@CIW305C8]\]. Interpatient pharmacokinetic variability with current agents, drug--drug interactions, toxicity concerns, and in some cases lack of efficacy \[[@CIW305C9]\], has led to the search for new agents in the treatment of these invasive fungi. In this particular group of patients the ability to use both parenteral and oral agents is clinically important during management.

Isavuconazole (ISAV) is a novel triazole with a broad-spectrum of antifungal activity administered as a water-soluble prodrug, isavuconazonium sulfate. In vitro and animal studies have demonstrated potential utility in the treatment of invasive aspergillosis \[[@CIW305C10]\], mucormycosis \[[@CIW305C11]\], candidiasis \[[@CIW305C12]\], and certain endemic mycoses \[[@CIW305C13], [@CIW305C14]\]. Both oral and intravenous formulations exist as the prodrug isavuconazonium sulfate which undergoes cleavage by plasma esterases to the active moiety ISAV. ISAV has been approved for use in the treatment of aspergillosis and mucormycosis following the completion of phase 3 trials \[[@CIW305C15], [@CIW305C16]\]. Pharmacokinetics are facile because there is no demonstrable food effect with oral administration \[[@CIW305C17]\], interpatient pharmacokinetic variability is minimal \[[@CIW305C18]\], and the intravenous prodrug formulation does not require the addition of cyclodextrin to achieve solubility and therefore can be used in patients with reduced renal function \[[@CIW305C19]\].

We evaluated the results of a phase 3 study performed to determine the safety and efficacy of ISAV as primary or salvage therapy in the treatment of either cryptococcosis or dimorphic mycoses.

METHODS {#s2}
=======

Study Design {#s2a}
------------

VITAL (ClinicalTrials.gov, NCT00634049) was a phase 3, open-label, nonrandomized trial conducted in 34 medical centers worldwide that evaluated the efficacy, safety, and outcomes of patients treated with ISAV for dimorphic fungi, emerging molds and yeasts, or invasive aspergillosis in the setting of renal impairment. Only patients infected with cryptococcosis and dimorphic fungi are presented in this report.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

All patients enrolled in this subset of the VITAL study had proven infection with *Cryptococcus* or a dimorphic fungus by EORTC/MSG criteria \[[@CIW305C20]\]. Eligibility criteria included age ≥18 years, weight ≥40 kg, rate-corrected QTc interval \<500 ms, absence of severe liver injury, and no concurrent treatment with strong inhibitors or inducers of cytochrome P450. Patients who were intolerant or refractory to other antifungal agents were also eligible for enrollment in this study. Primary therapy was defined as the receipt of \<4 days of other systemic antifungal therapy within the 7 days preceding study enrollment. Dissemination was defined as any extrapulmonary infection (see [Supplementary Material](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw305/-/DC1)).

Administration of Study Drugs {#s2c}
-----------------------------

Patients received a loading regimen of ISAV 200 mg (administered as isavuconazonium sulfate 372 mg) every 8 hours for 6 doses, followed by ISAV 200 mg once daily. Patients were treated orally or intravenously at the investigator\'s discretion. Patients were evaluated daily for the first 3 days and, thereafter, on treatment days 7, 14, 28, 42, and 84. If therapy was required beyond day 84, patients were assessed monthly. Following discontinuation of ISAV, for any reason, patients underwent end of therapy (EOT) assessment and 2 post-treatment monthly assessments. At days 42, 84, and EOT, investigators documented clinical, radiological, and mycological responses to therapy.

Study Oversight {#s2d}
---------------

The sponsors, Basilea Pharmaceutica International Ltd (Basel, Switzerland) and Astellas Pharma Global Development, Inc. (Northbrook, Illinois) designed the study protocol. Individual site investigators and central laboratories provided all study data. Study analysis was performed by the sponsors and they vouch for the integrity and validity of all data. All authors agreed to submit the manuscript for publication. The study was conducted in accordance with the Declaration of Helsinki (2000) and the International Conference on Harmonisation Guidelines for Good Clinical Practice. The institutional review board at each medical center approved the study. All patients provided written informed consent prior to enrollment.

Efficacy and Safety Assessments {#s2e}
-------------------------------

An independent data-review committee (DRC) verified the diagnostic certainty of all IFDs and provided a judgment for each assessment component (clinical, radiological, and mycological responses) and for the overall response for each patient. Overall responses were classified as complete or partial responses (both considered a treatment success), stable or progressive disease (both considered treatment failure), based on these assessments and following prespecified criteria (see [Supplementary Materials](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw305/-/DC1)).

The primary study endpoint was DRC-assessed overall response at day 42. Prespecified secondary endpoints included assessments of overall, clinical, radiological and mycological responses at days 42, 84, and EOT, and all-cause mortality through days 42 and 84 of ISAV treatment. The treatment of the endemic mycoses and cryptococcosis is often prolonged and for this reason efficacy at EOT was used for final outcome assessments in this study.

Adverse events (AEs) and findings from the physical examination, laboratory tests, electrocardiograms, and imaging studies were recorded by the investigators at each study visit.

Laboratory procedures are outlined in the [Supplementary Materials](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw305/-/DC1). Patients had trough ISAV levels measured during study visits. Fungal isolates from study participants underwent central laboratory identification and susceptibility testing.

Antimicrobial Susceptibility Testing {#s2f}
------------------------------------

All isolates were tested in accordance with the Clinical and Laboratory Standards Institute M27-A3 methodology \[[@CIW305C21]\] at Case Western Reserve University or the Fungus Testing Laboratory (UT-San Antonio).

Plasma Isavuconazole Concentrations {#s2g}
-----------------------------------

Plasma levels of ISAV were measured on days 7, 14, 28, and presumed steady state (\>day 30) 1 hour prior to the next scheduled dose or 24 ± 1 hours after last dose. ISAV and the inactive cleavage product (prodrug moiety) concentrations in plasma samples were measured using a validated liquid chromatography-mass spectrometry/mass spectrometry (LC--MS/MS) method at Pharmaceutical Product Development Inc., Middleton, Wisconsin.

Statistical Analysis {#s2h}
--------------------

VITAL Study---patient characteristics, antifungal exposure, outcomes, AEs, and mortality were summarized using descriptive statistics. Deaths were considered failures for all DRC assessments.

RESULTS {#s3}
=======

A total of 149 patients were enrolled in the VITAL trial, of which 38 were diagnosed with cryptococcosis or a dimorphic mycosis. The patients (age, 20--79 years) were derived from 5 countries and 10 medical centers. Thirty-one of these 38 patients (81.6%) completed the study. Patients with specific mycoses included 9 with cryptococcosis (*C. neoformans*, n = 4; *C. gattii*, n = 3; *Cryptococcus* spp. not otherwise specified, n = 2), 9 with coccidioidomycosis, 3 with blastomycosis, 7 with histoplasmosis, and 10 paracoccidioidomycosis (Table [1](#CIW305TB1){ref-type="table"}). Most patients received ISAV as primary therapy (33/38, 87%) for these mycoses. The most common underlying conditions were diabetes mellitus (n = 5) and chronic obstructive pulmonary disease (COPD) (n = 2). Table 1.Response to Isavuconazole at the End of TreatmentPrimary DiagnosisNo. of Successful Outcomes at EOT (%)Cryptococcosis All types6/9 (67) Pulmonary3/4 (75) CNS4/5 (80) Non-CNS dissemination0/1 (0)Coccidioidomycosis Pulmonary5/9 (56)Blastomycosis All types1/3 (33) Pulmonary1/1 (100) Non-CNS dissemination0/2 (0)Histoplasmosis All types4/7 (57) Pulmonary3/5 (60) CNS1/1 (100) Non-CNS dissemination2/3 (66)Paracoccidioidomycosis All types8/10 (80) Pulmonary6/8 (75) CNS0/1 (0) Non-CNS dissemination6/6 (100)[^2]

Cryptococcosis {#s3a}
--------------

Most patients with cryptococcal infections received ISAV as primary therapy (6/9, 67%) (Table [2](#CIW305TB2){ref-type="table"}). Two patients received ISAV following intolerance to alternative fungal therapy---in 1 patient this followed 11 days of AMB therapy, in the other patient this followed 17 days receiving combined AMB deoxycholate and fluconazole. This latter patient had both disseminated nocardiosis and pulmonary cryptococcosis and died after only 6 days of ISAV treatment. The third patient not receiving ISAV as primary therapy was clinically refractory to AMB deoxycholate and fluconazole after 16 days of therapy. The median duration of ISAV therapy in these patients was 180 days (range 6--182 days). Six patients with cryptococcosis had a successful response (complete success in 2, partial success in 4), whereas stable disease was demonstrated in 2 other patients. Of the 2 patients intolerant to prior therapy, one was a partial responder to ISAV and the other exhibited progression of disease and was considered a failure. Eight of 9 patients survived through EOT (all-cause mortality 1/9 \[11%\]). Table 2.Treatment of CryptococcosisPatientAgeSexComorbiditySite of InfectionSpeciesPrimary or Salvage TherapyDuration of ISAV (days)Mycologic ResponseOverall DRC Assessment at EOT145MNonePulmonaryNOSPrimary therapy180Presumed persistenceStable Failure243MPolycythemia veraMeningitis*C. neoformans*Intolerance to 11 days of AMB-d180Sterile CSF day 11Partial success354FNonePulmonary and meningitis*C. gattii*Primary therapy181Sterile CSF day 14Partial success469FBladder CAPulmonary*C. neoformans*Primary therapy182Presumed eradicationPartial success534FNonePulmonary and meningitis*C. gattii*Primary therapy176Sterile CSF day 165Complete success620FNonePulmonary, meningitis and blood*C. gattii*Refractory to 16 days of AMB181Presumed eradicationPartial success766MHeart transplant pulmonary/CNS nocardiosisBone, skin and soft tissue*C. neoformans*Intolerance to 17 days AMB6Presumed persistenceDeath -- progression (Day 7)879MNSCLCPulmonaryNOSPrimary therapy75Presumed eradicationComplete success968MInterstitial lung diseaseMeningitis*C. neoformans*Primary therapy25CSF sterile day 24Stable failure[^3]

Coccidioidomycosis {#s3b}
------------------

All patients with coccidioidomycosis received ISAV as primary therapy for pulmonary infection (9/9, 100%); 1 patient had concomitant involvement of the pleura. All patients received ISAV for a median of 180 days (range 180--183 days). At EOT, complete or partial success was observed in 5/9 (56%) patients with complete success in 2, including the patient with pleuropulmonary disease. Those with partial success exhibited complete clearance of infection radiographically (n = 2) and a solitary pulmonary nodule (n = 1). The remaining 4/9 patients had stable disease at EOT. It is noteworthy that all 4 of these patients had diabetes mellitus and all 4 exhibited persistent radiographic abnormalities at EOT (fibrocavitary disease n = 2, and focal infiltrates n = 2). The DRC determined all 9 patients had a clinical response to therapy at EOT.

Blastomycosis {#s3c}
-------------

Three patients were treated with blastomycosis, and 2 of these received very short courses of therapy: 1 patient was intolerant to itraconazole therapy in the treatment of pulmonary and genitourinary blastomycosis and withdrew consent after 6 days of ISAV although no adverse effects of therapy were noted, whereas the other was treated with ISAV as primary therapy for blastomycosis. In this second patient, dissemination was confirmed (on day 2 of ISAV therapy) with lesions in the lung, spleen, and skin; ISAV was subsequently discontinued and liposomal AMB (L-AMB) initiated. This patient died on day 18 (following 16 days of L-AMB). A third patient with pulmonary blastomycosis received ISAV after intolerance to itraconazole (anorexia) and was treated for 331 days with a complete clinical and radiographic response to therapy at EOT.

Histoplasmosis {#s3d}
--------------

Seven patients were treated for histoplasmosis. All received ISAV as primary therapy -- 3 with primary pulmonary infection and 4 with dissemination including 1 with central nervous system (CNS) involvement. Patients were treated for a median of 180 days (range 85--327 days). Complete clinical and radiographic success was observed in the patient with CNS involvement after 178 days of treatment. Partial success was found in 3 patients: 2 with disseminated disease, and 1 with lung disease alone. Stable disease was documented in a heart transplant patient with isolated pulmonary infection, and progression (failure) was seen in 1 patient with dissemination and another with lung disease despite 185 days of ISAV. All patients were alive at EOT.

Paracoccidioidomycosis {#s3e}
----------------------

All 10 patients with *Paracoccidioides* infections received ISAV as primary therapy. Treatment was administered for a median of 180 days (range 27--182 days). Complete success was found in 1 patient with widespread dissemination after 180 days of treatment, and partial success was determined in 7/10 (70%), with 5 of these 7 presenting with disseminated paracoccidioidomycosis including 1 with AIDS (CD4 count = 144 cell/mm^3^). Progressive disease was observed in 2 patients, both of whom died on days 27 and 91 after starting ISAV.

Safety Results {#s3f}
--------------

Thirty-three (87%) patients experienced AEs. The most common AEs were vomiting (n = 8), nausea (n = 6), back pain (n = 5), and headache (n = 5). Twelve (32%) patients had a serious adverse event (SAE) reported. Three events (septic shock, pneumonia, and vomiting) were reported in 2 patients each. Other SAEs were reported in a single patient. Fourteen (36.8%) patients had a treatment-related AE (Table [3](#CIW305TB3){ref-type="table"}). No patients were discontinued from the study primarily due to an AE. Table 3.Number and Percentage of Patients With Treatment-related Adverse EventsAdverse Event^a,b^Total (N = 38) N (%)Overall14 (36.8)Vomiting3 (7.9)Phlebitis4 (10.5)Diarrhea2 (5.3)Nausea2 (5.3)Chest pain2 (5.3)GGT elevation2 (5.3)Paresthesia2 (5.3)Somnolence2 (5.3)[^4][^5][^6][^7]

In vitro Susceptibility Testing (MICs) {#s3g}
--------------------------------------

CLSI MIC data for ISAV were available for 22 isolates (Table [4](#CIW305TB4){ref-type="table"}): *Coccidioides*, 0.06--0.12 µg/mL (n = 6); *Cryptococcus gattii*, 0.008--0.12 µg/mL (n = 7); *C. neoformans*, 0.008--1.2 µg/mL (n = 6); *Histoplasma*, 0.03 µg/mL (n = 2); *Paracoccidioides*, 0.001 µg/mL (n = 1). *Blastomyces* isolates were not available for susceptibility testing. Table 4.Susceptibility of Endemic Fungi Infecting Patients With Primary Disease, Refractory or Intolerant to Treatment per Clinical and Laboratory Standards Institute StandardsSpeciesMIC Range (µg/mL)ISAVVRCPOSAMB*Cryptococcus* spp.^a^* C. neoformans* (n = 6)0.008--0.120.03--0.250.03--0.250.06--1.0* C. gattii* (n = 7)0.008--0.120.03--0.060.03--0.120.5--1.0*Coccidioides immitis* (n = 6)0.06--0.120.06--0.060.06--0.250.5--0.5*Histoplasma capsulatum* (n = 2)0.03--0.030.06--0.250.06--0.120.12--0.12*Paracoccidioides brasiliensis* (n = 1)0.001--0.0010.03--0.030.03--0.030.25--0.25[^8][^9]

Plasma Isavuconazole Concentrations {#s3h}
-----------------------------------

On day 7 median levels were 3.2 µg/mL (range 0.61--5.05 µg/mL), day 14 median levels were 3.86 µg/mL (range 0.88--5.98 µg/mL), day 28 median levels were 4.01 µg/mL (range 0.78--7.80 µg/mL), and assumed steady-state median levels were 4.05 µg/mL (range 1.09--8.96 µg/mL).

DISCUSSION {#s4}
==========

This study demonstrates that ISAV has antifungal activity as both primary and salvage therapy in patients with cryptococcosis and dimorphic fungal infections. A successful response to therapy was seen in 24/38 (63%) of all patients at the end of therapy and an overall 89% (34/38) survival rate. The majority of patients treated in this study received ISAV as primary therapy and a successful response was observed in patients with pulmonary, non-CNS dissemination, and CNS infections. Although patient numbers were small, this study found that both *C. neoformans* and *C. gattii* responded similarly to ISAV, and this agent was successfully used in the management of cryptococcal meningitis. In patients refractory to or unable to tolerate prior antifungal therapy, 60% (3/5) exhibited a successful response to ISAV suggesting a potential role for this antifungal agent in the salvage setting as well.

ISAV concentrations in the cerebrospinal fluid (CSF) and brain have been evaluated in animal models and as compassionate-use therapy during the *Exserohilum* fungal meningitis outbreak \[[@CIW305C22]\]. Data from these patients showed CSF levels of 29--131 ng/mL with CSF/bloodstream ratios similar to those observed with posaconazole and itraconazole \[[@CIW305C23], [@CIW305C24]\]. Despite CSF levels lower than those seen in the blood, efficacy in the treatment of CNS infections has been observed in several murine models of infection and brain/plasma ratios of 1.96 have been found in a rat model, suggesting ISAV may be concentrated in brain tissue \[[@CIW305C25]\]. Additionally, ISAV is equivalent to voriconazole in the reduction of brain fungal burden during the treatment of *Candida* infections \[[@CIW305C26]\], equivalent to L-AMB in a model of pulmonary and CNS *Rhizopus* infection \[[@CIW305C11]\], and as effective as fluconazole in a model of cryptococcal meningitis \[[@CIW305C27]\]. Cumulatively, these findings and our early results from human cryptococcal infections suggest a potential role for ISAV in the treatment of CNS mycoses.

The heterogeneity of these mycoses, including differences in the host severity of illness, site of infection, concurrent medications, antifungal drug costs, and comorbidities plays a major role in the selection of an antifungal agent for treatment. AMB formulations are frequently prescribed for patients with severe manifestations of endemic mycoses while fluconazole, itraconazole, posaconazole, or voriconazole are reserved for those with mild-to-moderate disease or as "step-down" therapy following a response or intolerance from induction AMB \[[@CIW305C1], [@CIW305C4]--[@CIW305C7]\]. Significant differences do exist between the triazoles with regard to efficacy, pharmacokinetics and pharmacodynamics, drug--drug interactions, and toxicity \[[@CIW305C28]\] and balancing these concerns, particularly for patients necessitating prolonged therapy, can be difficult.

Fluconazole, with limited potency, has a minor role in the treatment of blastomycosis, paracoccidioidomycosis, and histoplasmosis, and higher doses are frequently necessary for effectiveness against coccidioidomycosis \[[@CIW305C5]--[@CIW305C8]\]. It is generally used in cryptococcosis during either low burden infections or in non-CNS infections. There are patient tolerability and absorption concerns with itraconazole \[[@CIW305C9]\], and there are limited data on the efficacy of posaconazole in the treatment of blastomycosis and paracoccidioidomycosis. Voriconazole has been demonstrated to be effective in the treatment of these endemic fungi \[[@CIW305C29]--[@CIW305C31]\]. However, drug--drug interactions and concerns with long-term use are common during treatment \[[@CIW305C32], [@CIW305C33]\] and combined with limited clinical experience make this triazole an uncertain choice.

ISAV offers potential advantages over these agents. Lower MICs have been described with ISAV compared to fluconazole against a number of these pathogens \[[@CIW305C13]\]. Additionally, ISAV can be taken with or without food \[[@CIW305C17]\], interpatient pharmacokinetic differences appear minimal \[[@CIW305C18]\], and fewer side-effects have been found compared to voriconazole in a recently completed phase 3 study of invasive aspergillosis \[[@CIW305C15]\]. Further evaluation of ISAV in the treatment of these mycoses is needed, however, the potential advantages over existing agents is encouraging and this study supports further evaluation of this new triazole.

None of the patients reported here were discontinued from the study drug primarily due to an AE. Thirty of the patients received ISAV for \>175 days suggesting long-term therapy, which is often indicated in the treatment of these mycoses, is tolerable.

The nonrandomized nature of this study limits the ability to precisely compare the efficacy and safety of ISAV directly to other triazoles used during treatment of these mycoses. However, the response rate observed in this study is similar to those previously reported for fluconazole, itraconazole, posaconazole, and voriconazole in the treatment of endemic mycoses \[[@CIW305C30], [@CIW305C31], [@CIW305C34]--[@CIW305C38]\]. The low number of patients enrolled with blastomycosis also merits future evaluation in the treatment of this infection. Other groups not included in this study, such as patients with coccidioidal meningitis, sporotrichosis, and infection with *Talaromyces marneffei* (formerly *Penicillium marnefeii*) could be examined in future studies.

In summary, ISAV was effective in the treatment of this cohort of patients with cryptococcosis and dimorphic fungal infections and the observed outcomes in these patients suggest that it is a welcome addition to the limited antifungal armamentarium for clinicians dealing with these mycoses.

Supplementary Data {#s5}
==================

[Supplementary materials](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw305/-/DC1) are available at <http://cid.oxfordjournals.org>. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.
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[^1]: This work was presented in part at the 54th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2014, Washington D.C.

[^2]: Abbreviations: CNS, central nervous system; EOT, end of treatment.

[^3]: Abbreviations: AMB, amphotericin B; AMB-d, amphotericin B deoxcholate; CA, cancer; CNS, central nervous system; CSF, cerebrospinal fluid; DRC, data-review committee; EOT, end of therapy; ISAV, isavuconazole; NOS, not otherwise specified (species identification not performed); NSCLC, non-small cell lung cancer.

[^4]: Alopecia, headache, dizziness, dyspepsia, abdominal pain, palpitations, xerosis, seizure, insomnia, dyspnea, asthenia, epistaxis, injection site hemorrhage, injection site pain, back pain, musculoskeletal pain, liver disorder, hepatomegaly, schistosomiasis, depression each occurred once.

[^5]: Abbreviation: GGT, gamma-glutamyl transferase.

[^6]: ^a^ Patients may have experienced \>1 of each type of treatment-related adverse event.

[^7]: ^b^ No patients required treatment discontinuation or alteration due to adverse events.

[^8]: Abbreviations: AMB, amphotericin B; ISAV, isavuconazole; MIC, minimum inhibitory concentration; POS, posaconazole; VRC, voriconazole.

[^9]: ^a^ Thirteen *Cryptococcus* isolates were collected from 9 patients. *Blastomyces* isolates were not available for susceptibility testing.
